⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20159973 | 1.00 | — | — | |
| SCHEMBL6844562 | 0.86 | — | — | |
| SCHEMBL17488360 | 0.81 | — | — | |
| SCHEMBL19723229 | 0.81 | — | — | |
| SCHEMBL17488359 | 0.81 | — | — | |
| SCHEMBL21386086 | 0.79 | ADH1B (0.32) | — | |
| SCHEMBL18502882 | 0.79 | ADH1B (0.32) | — | |
| SCHEMBL8214008 | 0.74 | IRAK4 (0.34) | — | |
| SCHEMBL6142299 | 0.74 | IRAK4 (0.34) | — | |
| SCHEMBL14724552 | 0.74 | IRAK4 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3929203-A1 | DERIVATIVES OF AMPHOTERICIN B | Sfunga Therapeutics, Inc. (US) | 2021-12-29 | — | — | EP | disclosed |
| WO-2020249667-A1 | SULFONYLUREA DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020120606-A1 | NEW PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-06-18 | — | — | WO | disclosed |
| WO-2017114512-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND, AS WELL AS PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2017-07-06 | — | — | WO | disclosed |
| US-20160304548-A1 | Derivatives of Amphotericin B | ELION THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-9233979-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150266895-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20130224195-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | COSTALES ABRAN (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130224195-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | COSTALES ABRAN (US) | 2013-08-29 | — | — | US | disclosed |
| US-8415382-B2 | Substituted benzazoles and methods of their use as inhibitors of RAF Kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415382-B2 | Substituted benzazoles and methods of their use as inhibitors of RAF Kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-7691866-B2 | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691866-B2 | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090317359-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090317359-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2009-12-24 | — | — | US | disclosed |
| EP-1682126-B1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090035309-A1 | Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase | NOVARTIS AG | 2009-02-05 | — | — | US | disclosed |
| US-20090035309-A1 | Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase | NOVARTIS AG | 2009-02-05 | — | — | US | disclosed |
| US-7423150-B2 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2008-09-09 | — | — | US | disclosed |
| US-7423150-B2 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2008-09-09 | — | — | US | disclosed |